TY - JOUR
T1 - Postoperative chemotherapy for node-positive cervical cancer
T2 - Results of a multicenter phase II trial (JGOG1067)
AU - Matoda, Maki
AU - Takeshima, Nobuhiro
AU - Michimae, Hirofumi
AU - Iwata, Takashi
AU - Yokota, Harushige
AU - Torii, Yutaka
AU - Yamamoto, Yorito
AU - Takehara, Kazuhiro
AU - Nishio, Shin
AU - Takano, Hirokuni
AU - Mizuno, Mika
AU - Takahashi, Yoshiyuki
AU - Takei, Yuji
AU - Hasegawa, Tetsuya
AU - Mikami, Mikio
AU - Enomoto, Takayuki
AU - Aoki, Daisuke
AU - Sugiyama, Toru
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/6
Y1 - 2018/6
N2 - Objective: This multicenter phase II Japanese Gynecologic Oncology Group study (JGOG1067) was designed to evaluate the efficacy and safety of postoperative chemotherapy in patients with node-positive cervical cancer. Methods: Patients with stage IB–IIA squamous cervical cancer who underwent radical hysterectomy and were confirmed to have pelvic lymph node metastasis were eligible for this study. The patients postoperatively received irinotecan (CPT-11; 60 mg/m2 intravenously on days 1 and 8) and nedaplatin (NDP; 80 mg/m2 intravenously on day 1). Chemotherapy administration commenced within 6 weeks after surgery and was repeated every 28 days for up to 5 cycles. The primary endpoint of this study was the 2-year recurrence-free survival (RFS) rate. The secondary endpoints were the 5-year overall survival (OS) rate, 5-year RFS rate, and adverse events such as complications of chemotherapy and lower-limb edema. Results: Sixty-two patients were analyzed according to our protocol, among whom 55 (88.7%) completed 5 cycles of scheduled treatment. The median follow-up period was 66.1 months (range, 16.8–96.6 months). The 2-year and 5-year RFS rates were 87.1% (95% confidence interval [CI]: 75.9–99.3) and 77.2% (95% CI: 64.5–85.8), respectively. Fourteen patients (22.5%) experienced recurrence during the follow-up period, 8 of whom died of the disease. The 5-year OS rate in this study was 86.5% (95% CI: 74.8–93.0). Only 9.7% of the patients experienced lymphedema in their legs. Conclusion: Postoperative chemotherapy without radiotherapy was found to be very effective in high-risk patients with node-positive cervical cancer.
AB - Objective: This multicenter phase II Japanese Gynecologic Oncology Group study (JGOG1067) was designed to evaluate the efficacy and safety of postoperative chemotherapy in patients with node-positive cervical cancer. Methods: Patients with stage IB–IIA squamous cervical cancer who underwent radical hysterectomy and were confirmed to have pelvic lymph node metastasis were eligible for this study. The patients postoperatively received irinotecan (CPT-11; 60 mg/m2 intravenously on days 1 and 8) and nedaplatin (NDP; 80 mg/m2 intravenously on day 1). Chemotherapy administration commenced within 6 weeks after surgery and was repeated every 28 days for up to 5 cycles. The primary endpoint of this study was the 2-year recurrence-free survival (RFS) rate. The secondary endpoints were the 5-year overall survival (OS) rate, 5-year RFS rate, and adverse events such as complications of chemotherapy and lower-limb edema. Results: Sixty-two patients were analyzed according to our protocol, among whom 55 (88.7%) completed 5 cycles of scheduled treatment. The median follow-up period was 66.1 months (range, 16.8–96.6 months). The 2-year and 5-year RFS rates were 87.1% (95% confidence interval [CI]: 75.9–99.3) and 77.2% (95% CI: 64.5–85.8), respectively. Fourteen patients (22.5%) experienced recurrence during the follow-up period, 8 of whom died of the disease. The 5-year OS rate in this study was 86.5% (95% CI: 74.8–93.0). Only 9.7% of the patients experienced lymphedema in their legs. Conclusion: Postoperative chemotherapy without radiotherapy was found to be very effective in high-risk patients with node-positive cervical cancer.
UR - http://www.scopus.com/inward/record.url?scp=85045321898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045321898&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2018.04.009
DO - 10.1016/j.ygyno.2018.04.009
M3 - Article
C2 - 29661497
AN - SCOPUS:85045321898
SN - 0090-8258
VL - 149
SP - 513
EP - 519
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 3
ER -
